A detailed history of Vanguard Group Inc transactions in Ovid Therapeutics Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,089,393 shares of OVID stock, worth $4.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,089,393
Previous 2,976,308 3.8%
Holding current value
$4.02 Million
Previous $9.08 Million 73.8%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$0.7 - $3.34 $79,159 - $377,703
113,085 Added 3.8%
3,089,393 $2.38 Million
Q1 2024

May 10, 2024

SELL
$2.72 - $4.04 $36,635 - $54,414
-13,469 Reduced 0.45%
2,976,308 $9.08 Million
Q4 2023

Feb 14, 2024

BUY
$2.98 - $3.78 $69,612 - $88,300
23,360 Added 0.79%
2,989,777 $9.63 Million
Q3 2023

Nov 14, 2023

BUY
$3.23 - $3.97 $217,020 - $266,740
67,189 Added 2.32%
2,966,417 $11.4 Million
Q2 2023

Aug 14, 2023

BUY
$2.53 - $3.89 $730,223 - $1.12 Million
288,626 Added 11.06%
2,899,228 $9.51 Million
Q1 2023

May 15, 2023

BUY
$1.88 - $2.85 $54,268 - $82,268
28,866 Added 1.12%
2,610,602 $6.74 Million
Q4 2022

Feb 10, 2023

BUY
$1.43 - $1.89 $1,638 - $2,165
1,146 Added 0.04%
2,581,736 $4.8 Million
Q3 2022

Nov 14, 2022

BUY
$1.84 - $2.26 $83,720 - $102,829
45,500 Added 1.79%
2,580,590 $4.75 Million
Q2 2022

Aug 12, 2022

SELL
$1.69 - $3.31 $1.95 Million - $3.82 Million
-1,152,819 Reduced 31.26%
2,535,090 $5.45 Million
Q1 2022

May 13, 2022

BUY
$2.65 - $3.49 $650,021 - $856,065
245,291 Added 7.13%
3,687,909 $11.6 Million
Q4 2021

Feb 14, 2022

BUY
$3.13 - $3.73 $189,480 - $225,803
60,537 Added 1.79%
3,442,618 $11.1 Million
Q3 2021

Nov 12, 2021

SELL
$3.31 - $4.04 $408,970 - $499,166
-123,556 Reduced 3.52%
3,382,081 $11.4 Million
Q2 2021

Aug 13, 2021

BUY
$3.3 - $4.49 $11.6 Million - $15.7 Million
3,505,637 New
3,505,637 $13.7 Million

Others Institutions Holding OVID

About Ovid Therapeutics Inc.


  • Ticker OVID
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,419,400
  • Market Cap $91.5M
  • Description
  • Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...
More about OVID
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.